Clinical Trial Detail

NCT ID NCT02009397
Title A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors James Graham Brown Cancer Center
Indications

melanoma

Therapies

Sargramostim

Ipilimumab

Age Groups: adult

No variant requirements are available.